Maxcyte (MXCT) EBIT Margin (2020 - 2025)
Historic EBIT Margin for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to 207.19%.
- Maxcyte's EBIT Margin fell 350600.0% to 207.19% in Q3 2025 from the same period last year, while for Sep 2025 it was 155.65%, marking a year-over-year decrease of 539100.0%. This contributed to the annual value of 132.54% for FY2024, which is 155600.0% down from last year.
- Latest data reveals that Maxcyte reported EBIT Margin of 207.19% as of Q3 2025, which was down 350600.0% from 167.24% recorded in Q2 2025.
- Maxcyte's EBIT Margin's 5-year high stood at 24.09% during Q3 2021, with a 5-year trough of 207.19% in Q3 2025.
- Its 5-year average for EBIT Margin is 107.75%, with a median of 108.23% in 2024.
- As far as peak fluctuations go, Maxcyte's EBIT Margin skyrocketed by 622300bps in 2022, and later tumbled by -1177700bps in 2023.
- Maxcyte's EBIT Margin (Quarter) stood at 48.81% in 2021, then decreased by -11bps to 54.34% in 2022, then grew by 5bps to 51.68% in 2023, then plummeted by -187bps to 148.41% in 2024, then tumbled by -40bps to 207.19% in 2025.
- Its last three reported values are 207.19% in Q3 2025, 167.24% for Q2 2025, and 118.33% during Q1 2025.